Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

Allarity Therapeutics Europe ApS

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading...   Loading...

1000.0 Bankruptcy Risk  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.5%   Bankruptcy risk   8.0% 7.3% 11.8% 3.0% 3.8% 3.0% 9.5% 9.5%   Credit score (0-100)   32 34 20 56 50 56 26 26   Credit rating   BB BBB BB BBB BBB BBB BB BB   Credit limit (kDKK)   -0.0 -0.0 -0.0 0.0 0.0 0.0 -0.0 -0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Gross profit   -40,918 -27,706 -13,155 -79,617 -42,967 -49,354 0.0 0.0   EBITDA   -43,046 -32,117 -16,085 -79,641 -51,742 -55,615 0.0 0.0   EBIT   -46,651 -39,123 -16,909 -79,974 -170,425 -55,811 0.0 0.0   Pre-tax profit (PTP)   -34,098.0 -38,942.0 -20,907.0 -43,654.0 -173,647.0 -54,278.0 0.0 0.0   Net earnings   -30,821.0 -33,965.0 -18,557.0 -76,279.0 -142,438.0 -48,735.0 0.0 0.0   Pre-tax profit without non-rec. items   -34,098 -38,942 -20,907 -43,654 -173,647 -54,278 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Tangible assets total   248 173 67.0 52.0 185 138 0.0 0.0   Shareholders equity total   -94,539 -128,504 -147,061 386,284 243,758 195,023 -243,710 -243,710   Interest-bearing liabilities   119,257 157,284 172,222 20,019 68,861 103,239 243,984 243,984   Balance sheet total (assets)   32,888 40,280 38,172 498,792 365,943 362,236 274 274   Net Debt   119,238 151,677 172,122 5,004 66,545 102,937 243,984 243,984     See the entire balance sheet 1000.0 Volume  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   -40,918 -27,706 -13,155 -79,617 -42,967 -49,354 0.0 0.0   Gross profit growth   -24.0% 32.3% 52.5% -505.2% 46.0% -14.9% 0.0% 0.0%   Employees   3 6 3 0 5 5 0 0   Employee growth %   0.0% 100.0% -50.0% -100.0% 0.0% 0.0% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   32,888 40,280 38,172 498,792 365,943 362,236 274 274   Balance sheet change%   -26.9% 22.5% -5.2% 1,206.7% -26.6% -1.0% -99.9% 0.0%   Added value   -43,046.0 -32,117.0 -16,085.0 -79,641.0 -170,092.0 -55,615.0 0.0 0.0   Added value %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   -9,597 -13,644 -58 456,598 -237,223 -365 -348,569 0   Net sales trend   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   -3.0 -4.0 -5.0 -5.0 -5.0 -5.0 0.0 0.0   1000.0 Profitability  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A EBITDA %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   114.0% 141.2% 128.5% 100.4% 396.6% 113.1% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   -25.9% -23.6% -5.6% -11.4% -39.4% -14.8% 0.0% 0.0%   ROI %   -29.3% -25.2% -6.0% -12.7% -44.3% -17.0% 0.0% 0.0%   ROE %   -79.2% -92.8% -47.3% -35.9% -45.2% -22.2% 0.0% 0.0%   1000.0 Solidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Equity ratio %   -74.2% -76.1% -79.4% 77.4% 66.6% 53.8% -99.9% -99.9%   Relative indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   -277.0% -472.3% -1,070.1% -6.3% -128.6% -185.1% 0.0% 0.0%   Gearing %   -126.1% -122.4% -117.1% 5.2% 28.2% 52.9% -100.1% -100.1%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   3.3% 2.9% 6.6% 4.8% 7.3% 0.3% 0.0% 0.0%   1000.0 Liquidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Quick Ratio   0.4 0.3 1.3 0.5 0.1 0.1 0.0 0.0   Current Ratio   0.4 0.3 1.3 0.5 0.1 0.1 0.0 0.0   Cash and cash equivalent   19.0 5,607.0 100.0 15,015.0 2,316.0 302.0 0.0 0.0   1000.0 Capital use efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   -16,132.0 -49,313.0 4,497.0 -38,970.0 -93,790.0 -141,959.0 -121,992.0 -121,992.0   Net working capital %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   -14,349 -5,353 -5,362 0 -34,018 -11,123 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   -14,349 -5,353 -5,362 0 -10,348 -11,123 0 0   EBIT / employee   -15,550 -6,521 -5,636 0 -34,085 -11,162 0 0   Net earnings / employee   -10,274 -5,661 -6,186 0 -28,488 -9,747 0 0